A Compassionate Access Protocol For Those Patients Who Have Completed A4001029
Sponsor
ViiV Healthcare (Industry)
Overall Status
No longer available
CT.gov ID
NCT00801515
Collaborator
Pfizer (Industry)
1
23
Study Details
Study Description
Brief Summary
This is a compassionate study to provide continued access to maraviroc for only those subjects completing study A4001029 who are showing clinical benefit. Assessments of safety and tolerability of maraviroc when added to OBT will be continued.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Study Design
Study Type:
Expanded Access
Official Title:
A Compassionate Access Protocol For Those Patients Who Have Completed A4001029
Study Start Date
:
Aug 1, 2009
Actual Primary Completion Date
:
Jul 1, 2011
Actual Study Completion Date
:
Jul 1, 2011
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- Patients having completed study A4001029 in Canada and still deriving clinical benefit.
Exclusion Criteria:
- None
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Pfizer Investigational Site | Montreal | Quebec | Canada | H3G 1A4 |
Sponsors and Collaborators
- ViiV Healthcare
- Pfizer
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00801515
Other Study ID Numbers:
- A4001090
First Posted:
Dec 3, 2008
Last Update Posted:
Jul 25, 2011
Last Verified:
Jul 1, 2011